Reply: Causal Inference Challenges in Evaluating Baroreflex Activation Therapy for Transthyretin Amyloid Cardiomyopathy: A Critical Appraisal. [PDF]
Khanna NR +3 more
europepmc +1 more source
Advancing Diagnostics and Therapy in Transthyretin Amyloid Cardiomyopathy
Katarzyna Holcman, Michał Tkaczyszyn
openaire +4 more sources
Patient Perspectives on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Attributes. [PDF]
Kumar N +10 more
europepmc +1 more source
Social Determinants of Health and Outcomes in Transthyretin Amyloid Cardiomyopathy. [PDF]
Mallepally A +4 more
europepmc +1 more source
The Burden of Transthyretin Amyloid Cardiomyopathy on Caregivers and Patients in Japan: A Cross‑Sectional Real‑World Survey. [PDF]
Kitaoka H +7 more
europepmc +1 more source
Baroreflex Activation Therapy in a Patient With Transthyretin Amyloid Cardiomyopathy. [PDF]
Khanna NR +3 more
europepmc +1 more source
Survival in a Contemporary, Real-World, Matched Cohort of Patients with Transthyretin Amyloid Cardiomyopathy Treated vs Not Treated with Tafamidis. [PDF]
Aus dem Siepen F +4 more
europepmc +1 more source
Diagnostic Trends and Geographic Health Care Disparities Among Patients With Transthyretin Amyloid Cardiomyopathy. [PDF]
Mitchell JD +6 more
europepmc +1 more source
Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data. [PDF]
Quader T +11 more
europepmc +1 more source

